European Association for the Study of the Liver Congress 2025 (EASL 2025)

Amsterdam, the Netherlands 07 May 2025 - 10 May 2025

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

Treatment with resmetirom improves liver stiffness, fibrosis biomarkers, and risk scores for clinically significant portal hypertension (CSPH) in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis at 2 years, according to a study.

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

17 hours ago

Does long-term albumin therapy prolong survival in cirrhotic patients?

a day ago by

Long-term human albumin (LTA) therapy among cirrhotic patients with existing or prior ascites and acute decompensation results in improved transplant-free survival (TFS), mortality, and disease-related complications, according to the results of the PRECIOSA trial.

Does long-term albumin therapy prolong survival in cirrhotic patients?

a day ago